Vera Therapeutics Inc (VERA)
41.38
-0.56
(-1.34%)
USD |
NASDAQ |
May 17, 16:00
41.38
0.00 (0.00%)
After-Hours: 20:00
Vera Therapeutics Cash from Investing (Quarterly): -219.29M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -219.29M |
| December 31, 2023 | 18.56M |
| September 30, 2023 | 16.23M |
| June 30, 2023 | -86.45M |
| March 31, 2023 | 12.23M |
| December 31, 2022 | 13.44M |
| September 30, 2022 | -2.44M |
| June 30, 2022 | -42.09M |
| March 31, 2022 | -39.46M |
| Date | Value |
|---|---|
| December 31, 2021 | -5.00M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.796M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.057M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | -0.047M |
| March 31, 2020 | -0.052M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-219.29M
Minimum
Mar 2024
18.56M
Maximum
Dec 2023
-19.62M
Average
--
Median
Sep 2020
Cash from Investing (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | -2.136B |
| Alpine Immune Sciences Inc | -2.562M |
| Fate Therapeutics Inc | 17.31M |
| Mersana Therapeutics Inc | -72.55M |
| Equillium Inc | -2.831M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -33.83M |
| Cash from Financing (Quarterly) | 276.54M |
| Free Cash Flow | -99.72M |
| Free Cash Flow Per Share (Quarterly) | -0.6637 |
| Free Cash Flow Yield | -5.24% |